Bianca Malagutti

This review indicates that TROP2-directed antibody-drug conjugates (ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings, and that although sacituzumab govitecan and datopotamab deruxtecan share TROP2 targeting and topoisomerase I inhibition, their safety profiles differ—sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis—differences attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake, with corresponding agent-specific, proactive and increasingly individualized preve

This review indicates that TROP2-directed antibody-drug conjugates (ADCs) are becoming increasingly integrated into breast cancer treatment across multiple disease settings, and that although sacituzumab govitecan and datopotamab deruxtecan share TROP2 targeting and topoisomerase I inhibition, their safety profiles differ—sacituzumab govitecan is mainly associated with neutropenia and diarrhoea, whereas datopotamab deruxtecan is characterized by stomatitis, ocular surface events and a low but clinically relevant risk of interstitial lung disease/pneumonitis—differences attributed to the integrated effects of payload, linker stability, drug-to-antibody ratio, tissue distribution and target-independent uptake, with corresponding agent-specific, proactive and increasingly individualized preve